V8 Peptides — Engineered Performance
Research Library
IGF-1 LR3 Mechanism of Action: Receptor Signaling
IGF-1 LR3Mechanism

IGF-1 LR3 Mechanism of Action: Receptor Signaling

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does IGF-1 LR3 act in cell models? IGF-1 LR3 binds the IGF-1 receptor, a receptor tyrosine kinase, and triggers autophosphorylation and recruitment of adaptor proteins such as IRS-1 and Shc. Those events feed two main branches: PI3K/Akt (linked to survival, protein synthesis and metabolism in cell models) and Ras/MAPK (linked to proliferation and differentiation). What sets the analog apart is not a new pathway but weak binding to IGF-binding proteins, so more ligand reaches the receptor in serum-containing or conditioned medium. Standard readouts are phospho-IGF-1R, phospho-Akt and phospho-ERK.

IGF-1 LR3 does not invent a signaling pathway. It is an engineered version of insulin-like growth factor 1 and uses the pathway that IGF-1 already uses. What changed is access: the analog escapes most of the binding-protein system that normally restrains IGF-1. This article walks through the receptor, the two main downstream branches, the role of binding proteins and receptor hybrids, and the readouts used in the laboratory to follow signaling. It describes cell and animal model findings only. For laboratory research use only; not for human consumption.

The receptor: a ligand-activated tyrosine kinase

The IGF-1 receptor (IGF-1R) is a heterotetramer of two extracellular alpha subunits, which bind ligand, and two transmembrane beta subunits that carry the intracellular tyrosine kinase domain. Structure and function of this receptor are reviewed by Adams and colleagues (2000) and, for signaling pathways, by Hakuno and Takahashi (2018). Ligand binding shifts the receptor into an active conformation, the kinase domains trans-phosphorylate each other on activation-loop tyrosines, and the phosphorylated receptor becomes a docking site for adaptor proteins.

IGF-1 LR3 retains the portions of IGF-1 needed for receptor engagement. The Arg3 substitution and N-terminal extension that define the analog are located in a region that mainly affects binding-protein interaction rather than the receptor-contact surface, which is why the analog remains active at IGF-1R (Bayne et al., 1988; Tomas et al., 1992). A fuller account of those changes is in the IGF-1 LR3 explainer.

Adaptors and the two main branches

After receptor autophosphorylation, the substrates IRS-1/2 and Shc are recruited and phosphorylated. They launch two principal cascades.

BranchKey stepsTypical cell-model readoutsReported cellular context
PI3K / AktIRS phosphorylation → PI3K → PIP3 → PDK1 and mTORC2 → Akt (Ser473, Thr308) → mTORC1, GSK3, FoxOPhospho-Akt, phospho-S6, phospho-GSK3, FoxO localizationSurvival, protein synthesis and metabolic signaling in cultured cells (Schiaffino and Mammucari, 2011)
Ras / MAPKShc/Grb2/SOS → Ras → Raf → MEK → ERK1/2Phospho-ERK, immediate-early gene expression, cyclin D1Proliferation and differentiation programs in cultured cells (Hakuno and Takahashi, 2018)

Which branch dominates depends on the cell type and the time after stimulation. In skeletal muscle culture, for example, Rommel and colleagues (2001) described IGF-1-induced myotube hypertrophy as mediated by PI3K/Akt/mTOR and PI3K/Akt/GSK3 signaling, with the Akt branch distinct from the mitogenic response. The point for experimental design is that one phospho-readout does not describe the whole response. Measuring both Akt and ERK, at several time points, avoids reading a cell line's bias as a property of the ligand.

Where the analog differs: IGF-binding proteins

Six IGF-binding proteins (IGFBP-1 to IGFBP-6) bind IGF-1 with affinity similar to or higher than the receptor's own. They are produced by many cell types and are present in serum, so in many culture setups the IGF-1 added to medium is partly captured before it reaches the receptor. Clemmons (1998) and Baxter (2000) review how these proteins both restrain and, in some circumstances, enhance IGF action, and that some have receptor-independent effects.

For the analog, reduced binding-protein affinity means the free ligand concentration at the cell surface is closer to the nominal concentration. This explains the reported higher potency of IGF-1 variants relative to IGF-1 in animals and in culture (Tomas et al., 1992, 1993) and the analog's use in serum-free media. It also explains a caution: a potency comparison between LR3 and native IGF-1 depends on how much binding protein the system contains. In a binding-protein-free buffer the two may look similar; in a conditioned medium rich in IGFBPs they will not.

Receptor hybrids and insulin receptor cross-talk

IGF-1R is closely related to the insulin receptor, and cells that express both can assemble hybrid receptors with one half of each. Hybrids bind IGF ligands preferentially and can shift the balance between metabolic and mitogenic signaling, as reviewed by Hakuno and Takahashi (2018). Two practical points follow. At high concentrations IGF ligands can cross-activate the insulin receptor, so a selectivity control (for example blocking IGF-1R with a receptor-specific antibody or inhibitor) is needed before a response is attributed to IGF-1R alone. And a cell line's ratio of insulin receptor to IGF-1R should be documented, because it changes the response to the same ligand.

Experimental readouts and controls

A signaling experiment with the analog is easier to interpret with a defined set of controls.

  • Serum starvation. A short period in low-serum or serum-free medium lowers background phosphorylation before stimulation.
  • Time course. Receptor and Akt phosphorylation peak within minutes; ERK phosphorylation and gene expression follow; protein-synthesis or proliferation readouts need hours to days.
  • Dose series. Stimulate across a concentration range and plot a curve rather than testing one point; concentrations come from the formula in the reconstitution volume guide and the calculator.
  • Receptor inhibition. Include an IGF-1R-selective inhibitor or blocking antibody arm.
  • Pathway inhibitors. A PI3K inhibitor or MEK inhibitor arm shows which branch carries the response.
  • Native IGF-1 comparison. Run a matched arm so the binding-protein effect is visible rather than assumed.
  • Vehicle and carrier. Match solvent and carrier protein in the control, since both can influence adsorption and background signaling.

Assigning a response to a branch

Kinase and pathway reagents commonly used to assign a response to a branch are summarized below as a design aid; choose them by target, not by brand, and confirm selectivity in the cell line used.

Reagent classTargetWhat a loss of response indicates
IGF-1R-selective inhibitor or blocking antibodyIGF-1 receptor kinase or ligand-binding domainResponse runs through IGF-1R, not insulin receptor cross-activation
PI3K inhibitorPI3K catalytic subunitsResponse depends on the Akt branch
Akt or mTOR inhibitorAkt, mTORC1Response sits downstream of PI3K, in growth or protein-synthesis control
MEK inhibitorMEK1/2Response depends on the ERK branch
IGFBP supplementationExcess binding protein in the mediumSensitivity to ligand sequestration; expected to blunt native IGF-1 more than the analog

Reading these arms together turns a single stimulation into a map of which branch carries the response, and the IGFBP arm tests directly whether the analog's reduced binding-protein affinity is relevant in the system at hand.

Negative feedback and signal termination

Signaling is self-limiting. Activated IGF-1R is internalized and either recycled or degraded, IRS proteins are phosphorylated on serine residues by mTORC1/S6K, which reduces their ability to couple to the receptor, and phosphatases such as PTEN and PTP1B remove the signals. In extended cultures this appears as a response that peaks and then declines even though ligand is still present. A decline in phospho-Akt at 24 hours therefore does not necessarily mean the ligand has degraded; a fresh addition or a receptor-level readout can distinguish the two explanations. This distinction is the same persistence question that arises in any extended culture.

What a mechanism study can and cannot claim

Mechanism experiments in cell lines show that a pathway can be engaged under defined conditions. They do not show which pathways are used in a different cell type, in a tissue, or in an intact organism, where binding proteins, local proteases and other hormones all participate. Reports of effects in animals, such as the dexamethasone and normal-rat studies cited above, address the whole-animal question separately and do not substitute for a pathway analysis. Likewise, the analog's identity and folding determine whether any of this holds for the material in the vial: a misfolded or aggregated preparation will give a weaker response than its mass suggests. Verification approaches are covered in the IGF-1 LR3 purity testing guide, and certificates, where published, are listed in the COA library.

Putting the mechanism to work at the bench

The IGF-1 LR3 product page lists a 1 mg lyophilized vial with HPLC purity of 98% or higher and states refrigerated storage at 2–8 °C, −20 °C for long-term holding. Because the molecule is protein-sized and disulfide-bonded, reconstitute gently, avoid foaming and aliquot, as described in the research overview. Record each stock's preparation date, since a mechanism study that spans weeks is only as reproducible as its ligand.

Related reading

Frequently asked questions

Which receptor does IGF-1 LR3 activate?

The IGF-1 receptor, a receptor tyrosine kinase. At high concentrations IGF ligands can also activate the insulin receptor or hybrid receptors, so a selectivity control is advisable.

Is the signaling pathway different from native IGF-1?

No. The analog uses the same receptor and the same PI3K/Akt and Ras/MAPK branches. The difference is weak binding to IGF-binding proteins, which changes how much free ligand reaches the receptor.

What are the standard readouts for activity?

Phospho-IGF-1R, phospho-Akt (Ser473) and phospho-ERK1/2 by immunoblot or immunoassay, plus proliferation or protein-synthesis assays for longer time scales.

Why measure both Akt and ERK?

The branches can respond differently by cell type and time. A single readout may reflect a cell line's bias instead of the ligand's overall effect.

Why does serum change the result?

Serum carries IGF-binding proteins that capture native IGF-1. Because the analog binds them weakly, its apparent potency relative to native IGF-1 is larger in serum-containing or conditioned medium.

What controls show the response is through IGF-1R?

An IGF-1R-selective inhibitor or blocking antibody arm, a matched native IGF-1 arm, and a vehicle-and-carrier control matched to the stock.

Why can signaling fade while ligand is still present?

Receptor internalization, serine phosphorylation of IRS proteins by mTORC1/S6K and phosphatase activity limit signaling over time, so responses can decline without ligand loss.

Does a pathway study show what happens in an organism?

No. A cell-line pathway study shows that signaling can be engaged under defined conditions; whole-animal behavior involves binding proteins, other hormones and tissue context.

How does handling affect a mechanism experiment?

Adsorption, aggregation and freeze–thaw all lower the active concentration. Low-binding plastic, gentle reconstitution and single-use aliquots keep the dose series meaningful.

Where is the product information?

The product page gives a 1 mg lyophilized vial, 98% or higher HPLC purity and storage guidance; certificates are in the COA library where published.

Related reading: IGF-1 LR3 Quality Testing: A Lab Verification Guide, How to Reconstitute IGF-1 LR3: A Lab Handling Guide, IGF-1 LR3 Complete Guide: Where the Research Fits.

References

  1. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-1093. doi:10.1007/pl00000744
  2. Hakuno F, Takahashi SI. 40 years of IGF1: IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86. doi:10.1530/jme-17-0311
  3. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1:4. doi:10.1186/2044-5040-1-4
  4. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3(11):1009-1013. doi:10.1038/ncb1101-1009
  5. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140(1-2):19-24. doi:10.1016/s0303-7207(98)00024-0
  6. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976. doi:10.1152/ajpendo.2000.278.6.e967
  7. Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 IGF receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/s0021-9258(18)68777-0
  8. Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282:91-97. doi:10.1042/bj2820091

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.